Cytosorbents (CTSO) to Release Quarterly Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) will release its earnings data after the market closes on Thursday, March 14th. Analysts expect Cytosorbents to post earnings of ($0.13) per share for the quarter.

Cytosorbents Stock Up 3.1 %

NASDAQ CTSO traded up $0.03 during trading on Thursday, reaching $1.01. The company’s stock had a trading volume of 114,775 shares, compared to its average volume of 195,443. The stock has a market capitalization of $44.88 million, a PE ratio of -1.91 and a beta of 0.58. Cytosorbents has a 1-year low of $0.84 and a 1-year high of $4.29. The business has a 50-day moving average price of $0.99 and a 200-day moving average price of $1.48. The company has a current ratio of 1.61, a quick ratio of 1.36 and a debt-to-equity ratio of 0.23.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered Cytosorbents from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $5.50 to $1.00 in a report on Friday, December 29th.

Insider Transactions at Cytosorbents

In other Cytosorbents news, Director Alan D. Sobel bought 22,557 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was purchased at an average price of $1.33 per share, for a total transaction of $30,000.81. Following the purchase, the director now directly owns 101,857 shares in the company, valued at $135,469.81. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its holdings in shares of Cytosorbents by 41.2% in the 3rd quarter. Renaissance Technologies LLC now owns 197,796 shares of the medical research company’s stock worth $269,000 after buying an additional 57,676 shares in the last quarter. Jane Street Group LLC acquired a new position in Cytosorbents during the first quarter worth $211,000. CIBC Private Wealth Group LLC lifted its holdings in shares of Cytosorbents by 40.8% during the fourth quarter. CIBC Private Wealth Group LLC now owns 172,649 shares of the medical research company’s stock valued at $192,000 after acquiring an additional 50,000 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Cytosorbents by 21.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 57,684 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 10,141 shares in the last quarter. Finally, Morgan Stanley grew its holdings in shares of Cytosorbents by 7.5% in the 4th quarter. Morgan Stanley now owns 111,343 shares of the medical research company’s stock worth $173,000 after purchasing an additional 7,791 shares during the last quarter. Institutional investors own 34.23% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.